Vitamin D research has entered a renaissance in the past decade, with growing awareness of its pleiotropic actions beyond musculoskeletal health. Vitamin D defi ciency is now implicated in the pathogenesis of a wide range of conditions, including infection, vasculopathy, metabolic disorders and cancer, and the therapeutic potential of vitamin D is a topic of intense interest. In the current issue of Critical Care, Amrein and colleagues report the effi cacy and safety of a single dose of 540,000 units cholecalciferol (vitamin D 3 ), given orally/enterally, to critically ill patients [1] .
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Vitamin D research in acute critical care is in its infancy, due to the traditional bias of vitamin D defi ciency being a chronic condition. Th is belief has been overturned by recent studies associating vitamin D defi ciency with acute life-threatening hypocalcaemia, cardiac failure and increased mortality in critically ill patients [2, 3] . Whether vitamin D replacement improves outcomes in critically ill patients is unknown.
Vitamin D replacement in critically ill patients is theoretically problematic. Oral and enteral formulations may be ineff ective due to malabsorptive processes arising from gastrointestinal oedema and infl ammation. Th e intra muscular route is relatively contraindicated in patients with coagulopathy or in patients receiving anticoagulants. Intravenous supplementation up to 500 units daily in parenteral feed, more than doubling the conventional regime, failed to correct defi ciency [4] . Th e failure to achieve vitamin D suffi ciency in early studies has indicated the need for an alternative regime, but the effi cacy of high-dose vitamin D supplementation in critically ill patients has only been reported recently [1, 5] .
Th e defi nition of vitamin D suffi ciency in the general population is a subject of ongoing debate. Th e proposed optimal vitamin D level ranges from 20 to >32 ng/ml. While the optimal level in critical illness is yet to be defi ned, applying these cut-off points means a single dose of 540,000 units cholecalciferol, used in the current study [1] , is capable of restoring vitamin D suffi ciency in critically ill patients as early as within 24 hours of administration (mean 25-hydroxyvitamin D (25(OH)D) >20 ng/ml) and certainly by 1 week (mean 25(OH)D >38 ng/ml). Th ese fi ndings are similar to those reported by another recent study demonstrating effi cacy of 120,000 units in divided doses [5] .
Th e increment of 25(OH)D in the current study (~22 ng/ml by day 3) stands in contrast to that reported in the general population. Th e mean rise in 25(OH)D 3 days after a similar single dose (300,000 to 600,000 units) of cholecalciferol was two or three times higher (40 to 60 ng/ml) in community-dwelling individuals [6, 7] . While baseline vitamin D status and obesity may determine response to vitamin D supple ments [8] , baseline 25(OH)D concen trations were not markedly diff erent (13 to 15 ng/ml) and the reported mean body mass index was <30 kg/m 2 in these studies. Th ese intriguing diff erences have shed light on the pathogenesis of vitamin D defi ciency in critical illness. Lesser increments in 25(OH)D concentration in critically ill patients, as observed in the current study, may relate to impairment in absorption, hydroxylation or vitamin D transport. Another hypothesis is an increase in tissue vita min D requirement during critical illness, resulting in Abstract Vitamin D defi ciency is highly prevalent among critically ill patients and may be associated with adverse outcomes. Failure of conventional vitamin D supplementation in correcting defi ciency has called for studies to evaluate the effi cacy and safety of a highdose regime in critically ill patients. High-dose vitamin D supplementation that corrects a defi cient state eff ectively and safely allows for intervention studies to be undertaken to determine the impact of vitamin D on morbidity and mortality in critically ill patients.
heightened conversion of 25(OH)D to active 1,25-dihydroxy vitamin D on a tissue level [3] . Th is is supported by the more severe degree of secondary hyperparathyroidism at baseline and the surge in 1,25-dihydroxy vitamin D concentration shortly after vitamin D replacement in the critically ill population.
Collectively these results suggest a higher replacement dosage may be required in critically ill patients compared to the general population, implying critically ill patients may be more defi cient than the measured serum 25(OH)D concentrations indicate. Future studies should evaluate changes in vitamin D metabolites, their binding proteins and the parathyroid axis following diff erent dosing regimes, to determine how vitamin D metabolism, tissue requirement and renal handling of metabolites are aff ected during critical illness.
If critically ill patients are profoundly defi cient in vitamin D due to increased tissue requirement for this pleiotropic hormone for immune defence and metabolic regulation, does vitamin D treatment improve outcome? Th is is reminiscent of the growth hormone story, with similar enthusiasm over the potential benefi ts of growth hormone in critical illness a decade ago, which ended in disappointment when studies showed that high-dose growth hormone treatment increased mortality [9] .
Is high-dose vitamin D supplementation safe in critically ill patients? Th e current study revealed no occurrence of hypercalcaemia in any patients, as supported by similar safety data in the general population. A recent randomised controlled trial surprisingly revealed an increased risk of falls and fractures in communitydwelling women treated with a single dose of 500,000 units oral cholecalciferol [10] , thus raising safety concerns surrounding high-dose supplementation, inde pendent of hypercalcaemia. Causes of this unexpected harm are unclear but could be related to stunning from the ultra high dose and protective upregulation of the enzyme 25-hydroxyvitamin D-24-hydroxylase, which catabolises 1,25-dihydroxy vitamin D, thus paradoxically reducing its tissue level [11] . A more physiologic regime consisting of more frequent dosing of lesser amounts of vitamin D may be similarly eff ective and should be tested in critically ill patients.
Th ere is currently tantalising circumstantial evidence supporting a therapeutic role for vitamin D in critical illness. An eff ective vitamin D dosing regime will set the stage for undertaking intervention studies to investigate the impact of vitamin D supplementation on outcomes in critical illness. We wait eagerly for vitamin D to declare its true identity: is it a novel pleiotropic saviour, or another bystander in critical illness? Abbreviations 25(OH)D, 25-hydroxyvitamin D.
